Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated May 22, 2023 (3 years ago)

Pain Reliever (Acetaminophen)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: firm's investigation due to customer complaints for discoloration found that the product was out of specification for an impurity.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Pain Reliever, Acetaminophen USP Caplets, 500 mg, 225-count bottles packaged in a cardboard carton, Distributed by: Walgreen Co., 200 Wilmot Rd, Deerfield, IL 60015; NDC 0363-9947-35.

Affected NDC 0363-9947-35

Compare with the code on your package — it is the most precise check available.

Drug: Acetaminophen Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Pain Reliever
Acetaminophen
NDC 00363-9947
500 mg/1 Tablet
Oral
Walgreen CO. OTC
Recalling firm
Aurobindo Pharma USA Inc.
NDC code
0363-9947-35
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0765-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Acetaminophen recalls

See all
Class II · Moderate risk

Tylenol

Defective Container

Ongoing Packaging defect Kenvue Brands LLC D-0121-2026
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026

Other recalls by Aurobindo Pharma USA Inc.

All 2023 recalls
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk

Nebivolol Tablets

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025